Bendell

DS-7300 Phase 2 Trial Initiated in Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

Retrieved on: 
Wednesday, July 20, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, DXD, Patient, Diagnosis, Sustainable development, Bachelor of Pharmacy, Veni, vidi, vici, Daiichi Sankyo, ADC, Immunoglobulin G, Bendell, Doctor of Philosophy, Lung cancer, Cardiovascular disease, Prostate cancer, Survival rate, Cleavage, TSE, Safety, Cancer, Progression-free survival, American Cancer Society, HIV disease progression rates, Quality of life, PD-L1, Immunotherapy, Technology, Disease, ORR, Senior, Pharmacokinetics, Sarah Cannon Research Institute, SCLC, Pharmaceutical industry, Medical imaging

Daiichi Sankyo (TSE: 4568) announced today that the first patient has been dosed in a global phase 2 trial evaluating the efficacy and safety of DS-7300 in patients with pretreated extensive-stage small cell lung cancer (SCLC).

Key Points: 
  • Daiichi Sankyo (TSE: 4568) announced today that the first patient has been dosed in a global phase 2 trial evaluating the efficacy and safety of DS-7300 in patients with pretreated extensive-stage small cell lung cancer (SCLC).
  • Based on the encouraging results seen in the ongoing phase 1/2 trial, we have initiated this phase 2 trial of DS-7300 to further evaluate whether targeting B7-H3 with our DXd antibody drug conjugate technology may become a potential treatment option for patients with extensive-stage small cell lung cancer.
  • B7-H3 is overexpressed in a wide range of cancer types, including SCLC, squamous non-small cell lung cancer and prostate cancer.
  • In addition to the phase 2 trial in extensive-stage SCLC, DS-7300 is being evaluated in a phase 1/2 trial in collaboration with the Sarah Cannon Research Institute in three cohorts of patients with metastatic squamous non-small cell lung cancer, esophageal squamous cell carcinoma and castration-resistant prostate cancer.

DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid Cancers

Retrieved on: 
Friday, September 17, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Prostate, Congress, Patient, Sustainable development, Lung cancer, Index (publishing), Immunoglobulin G, Safety, Head, Adult, Dehydration, Causality, Breast, Breast cancer, Chills, Bendell, Progression-free survival, Interstitial lung disease, Plexxikon, Research, Bachelor of Pharmacy, Oncology, Thought, Bladder cancer, DXD, CRO, Veni, vidi, vici, Fatigue, Endometrial cancer, ILD, MD, ADC, Anemia, Cancer, Squamous cell carcinoma, Lymphocyte, Laboratory, Vomiting, Appetite, European Society for Medical Oncology, Death, Cardiovascular disease, Senior, MTD, Sarah Cannon Research Institute, Melanoma, Quality of life, Technology, Oncotarget, Doctor of Philosophy, PRS, RDE, Cleavage, Nausea, Daiichi Sankyo, Diarrhea, Fever, Lung, Pharmaceutical industry, Medical imaging, Fine chemical, Silviculture, B7-H3, the DS-7300 Study, DS-7300, Daiichi Sankyo in Oncology, B7-H3, THE DS-7300 STUDY, DS-7300, DAIICHI SANKYO IN ONCOLOGY

New first-in-human data from DS-7300, a B7-H3 directed DXd antibody drug conjugate (ADC) being developed in strategic collaboration between Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute, showed promising early clinical activity in patients with several types of advanced solid tumors.

Key Points: 
  • New first-in-human data from DS-7300, a B7-H3 directed DXd antibody drug conjugate (ADC) being developed in strategic collaboration between Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute, showed promising early clinical activity in patients with several types of advanced solid tumors.
  • DS-7300 was tolerated across all dose levels (0.8 mg/kg -16.0 mg/kg) with no dose-limiting toxicities observed in 70 patients enrolled.
  • Stable disease has been reported in an additional 32 patients including 24 patients who are still being treated with various doses of DS-7300 as of data cut-off of July 21, 2021.
  • Patients enrolled in the dose escalation study received a median of four prior lines of therapy (range, 1-10).

Cloudinary Identifies Opportunities to Raise Visual Storytelling Impact in its Inaugural State of Visual Media Report.

Retrieved on: 
Tuesday, May 14, 2019
Technology, Data management, Internet, Networks, Audio, Video, Communications, Marketing, Communication design, Marketing, Design, Brand, Graphic design, Product management, Arent, Storytelling, Advertising, Bendell, Market economics), Technology, Data management, Internet, Networks, Audio, Video, Communications, Marketing, Communication design, Marketing, Design, Brand, Graphic design, Product management, Arent, Storytelling, Advertising, Bendell, Market economics)

Cloudinary , the end-to-end media management platform for the worlds top brands, today launched its inaugural State of Visual Media report, revealing the ways in which fully optimized rich media are vital to successful visual storytelling.

Key Points: 
  • Cloudinary , the end-to-end media management platform for the worlds top brands, today launched its inaugural State of Visual Media report, revealing the ways in which fully optimized rich media are vital to successful visual storytelling.
  • Yet too often these business critical media assets arent optimized to their full potential.
  • Slow-to-load or mis-cropped images can be directly tied to lost opportunities, while beautiful, engaging media can be attributed to upticks in social shares and improved bottom lines.
  • Brands understand that strong visual experiences engage users, create loyalty and drive revenue, said Colin Bendell, Senior Director of Strategy and Analytics, Cloudinary.